Fig. 5.

PRLR-DbsAb inhibits PRLR-expression tumor growth in vivo. sc Tumor cells plus sc effector cells (E/T 1:4) model: (a) Schematic schedule of inoculating tumor and treatment. A total of 1* 10⁷ T47D cells and 2.5* 10⁶ unstimulated huPBMCs were injected into mice and inoculated mice were administered with weekly intraperitoneal administration of 5 ml/kg PBS, 3 mg/kg PRLR, 0.33 mg/kg, 1 mg/kg, or 3 mg/kg PRLR-DbsAb (n=6-7); (b) T47D tumor sizes. Data were presented as measured tumor volume from different mouse; (c) T47D tumor sizes. Data were presented as Mean ±SEM ; (d) The digital image of stripped tumor; (e) Stripping tumor weight. Sc tumor cells plus ip effector cells (1:1) model: (f) Schematic schedule of inoculating tumor and treatment; (g) T47D tumor sizes. Data were presented as Mean ±SEM (n=3); (h) the digital image and weight of stripped tumor; (i) Mouse growth curve. * and ** mean compared with the placebo group, *P <0.05 and **P <0.01. ^#, ^## and ^### mean compared with the PRLR mAb group, ^#P <0.05, ^##P <0.01 and ^###P <0.001.